Brensocatib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Brensocatib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
17
Registered trials
19
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Brensocatib can convert its Small molecule drug profile and DPP-1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Brensocatib (query alias: brensocatib) |
|---|---|
| Modality / target | Small molecule drug; DPP-1; DPP-1 inhibitors |
| Highest global status | Approved |
| Originator | Insmed, Inc. |
| Active developers | Insmed, Inc., Insmed Netherlands BV |
The MCP disease footprint includes Non-cystic fibrosis bronchiectasis, Bronchiectasis, Chronic rhinosinusitis without nasal polyps. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06013241 | Phase 2 | Completed | 288 | Change From Baseline to the 28-day Average of Daily Sinus Total Symptom Score (sTSS) at Week 24 |
| NCT06685835 | Phase 2 | Terminated | 214 | Percent Change From Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Week 16 |
| NCT06344728 | Phase 1 | Completed | 24 | Relative Bioavailability Between Brensocatib Pediatric Oral Solution and Oral Tablets for Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC∞) of Brensocatib in Plasma |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
Phase 2; n=29; evaluation: not stated. Reported fields: -; -; -
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) 6 The BiRCh Study
Phase 2; n=288; evaluation: Positive. Reported fields: TEAE(discontinuation) = 3.0 % ; TEAE(discontinuation) = 3.0 % ; TEAE(discontinuation) = 2.0 %
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study
Phase 3; n=1767; evaluation: not stated. Reported fields: Annualized Rate of Pulmonary Exacerbations (PEs) = 1.286 exacerbation per participant-year (95% Confidence Interval, 1.158 - 1.428); Annualized Rate of Pulmonary Exacerbations (PEs) = 1.015 exacerbation per participant-year (95% Confidence Interval, 0.910 - 1.132); Annualized Rate of Pulmonary Exacerbations (PEs): Rate ratio = 0.789(95% CI, 0.680 - 0.916), P-Value = 0.0019; Rate ratio = 0.806(95% CI, 0.694 - 0.936), P-Value = 0.0046
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Brensocatib addresses Non-cystic fibrosis bronchiectasis, Bronchiectasis, Chronic rhinosinusitis without nasal polyps. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-08-13 | PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis | Approved | Financial terms not disclosed |
| 2025-08-13 | VytlOne Announces New Partnership with Insmed | Approved | Financial terms not disclosed |
| 2016-10-05 | Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor | Phase 2 | US$30.0M upfront; US$120.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
